Early clinical and pharmacokinetic results of lower dose fludarabine and cyclophosphamide, and high dose rituximab (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL).

被引：2
|
作者：
Tarhini, Ahmad A. [1 ]
Land, S. [1 ]
Meisner, D. [1 ]
Pietragallo, L. [1 ]
Sulecki, M. [1 ]
Lim, F. [1 ]
Kiefer, Gauri J. [1 ]
Pinkerton, R. [1 ]
Obsom, J. [1 ]
Sukaly, S. [1 ]
Schaefer, P. M. [1 ]
Foon, Kenneth A. [1 ]
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2844.2844
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2844
引用
收藏
页码：805A / 805A
页数：1
相关论文
共 50 条
  • [1] Final results of lower dose fludarabine (F) and cyclophosphamide (C), and high dose rituximab (R), (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL)
    Tarhini, Ahmad A.
    Land, S.
    Pietragallo, L.
    Laman, A.
    Sulecki, M.
    Marks, S.
    Meisner, D.
    Schaefer, P. M.
    Foon, Kenneth A.
    BLOOD, 2007, 110 (11) : 606A - 607A
  • [2] Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience
    Tadmor, Tamar
    Herishanu, Yair
    Braester, Andrei
    Bairey, Osnat
    Aviv, Ariel
    Rahimi-Levene, Naomi
    Fineman, Riva
    Levi, Itai
    Yuklea, Mona
    Ruchlemer, Rosa
    Shvideland, Lev
    Polliack, Aaron
    BLOOD, 2018, 132
  • [3] Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia
    Mato, Anthony R.
    Foon, Kenneth A.
    Feldman, Tatyana
    Schuster, Stephen J.
    Svoboda, Jakub
    Chow, Kar Fai
    Valentinetti, Marisa
    Mrkulic, Mary
    Azzollini, Kelly
    Gadaleta, Gabriella
    Bhattacharyya, Pritish K.
    Zenreich, Joshua
    Pascual, Lauren-Nicole
    Yannotti, Kara
    Kdiry, Sabrina
    Howlett, Christina
    Strelec, Lauren
    Porter, David
    Bejot, Coleen
    Goy, Andre
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 487 - 492
  • [4] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [5] Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
    Foon, Kenneth A.
    Boyiadzis, Michael
    Land, Stephanie R.
    Marks, Stanley
    Raptis, Anastasios
    Pietragallo, Louis
    Meisner, Dennis
    Laman, Andrew
    Sulecki, Mathew
    Butchko, Allyson
    Schaefer, Patricia
    Lenzer, Diana
    Tarhini, Ahmad
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 498 - 503
  • [6] The treatment of complicated and high risk chronic lymphocytic leukemia (CLL) with fludarabine, cyclophosphamide and rituximab (FCR).
    Donthireddy, V
    Shurafa, MS
    Saleh, M
    Kamboj, G
    Wang, D
    Janakiraman, N
    BLOOD, 2005, 106 (11) : 341B - 341B
  • [7] Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)
    Grifi, Fatiha
    Bougherira, Soraya
    Djenouni, Amel
    LEUKEMIA & LYMPHOMA, 2017, 58 : 94 - 94
  • [8] Early results of modified fludarabine, cyclophosphamide, and rituximab (mFCR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL).
    Tarhini, A. A.
    Land, S.
    Lim, F.
    Kiefer, G. J.
    Pietragallo, L.
    Pinkerton, R. A.
    Sulecki, M.
    Meisner, D.
    Schaefer, P. M.
    Foon, K. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [9] Therapy with fludarabine, cyclophosphamide and rituximab (FCR) for relapsed or untreated progressive chronic lymphocytic leukemia (CLL). A single center experience.
    Pavlovsky, Carolina
    Pavlovsky, Ntiago
    Pardo, Maria L.
    Sapia, Sandra
    Monreal, Maricla
    Corrado, Claudia
    Pavlovsky, Miguel A.
    Fernandez, Isolda
    Juni, Mariana
    BLOOD, 2006, 108 (11) : 329B - 329B
  • [10] Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL).
    Lamanna, N
    Weiss, MA
    Maslak, PG
    Gencarelli, AN
    Scheinberg, DA
    Horgan, D
    BLOOD, 2003, 102 (11) : 440A - 440A
12345